Cargando…

CEBPA–double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features

Mutations in CCAAT/enhancer binding protein α (CEBPA) occur in 5–10% of cases of acute myeloid leukemia. CEBPA-double-mutated cases usually bear biallelic N- and C-terminal mutations and are associated with a favorable clinical outcome. Identification of CEBPA mutants is challenging because of the v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mannelli, Francesco, Ponziani, Vanessa, Bencini, Sara, Bonetti, Maria Ida, Benelli, Matteo, Cutini, Ilaria, Gianfaldoni, Giacomo, Scappini, Barbara, Pancani, Fabiana, Piccini, Matteo, Rondelli, Tommaso, Caporale, Roberto, Gelli, Anna Maria Grazia, Peruzzi, Benedetta, Chiarini, Marco, Borlenghi, Erika, Spinelli, Orietta, Giupponi, Damiano, Zanghì, Pamela, Bassan, Renato, Rambaldi, Alessandro, Rossi, Giuseppe, Bosi, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394975/ https://www.ncbi.nlm.nih.gov/pubmed/28250006 http://dx.doi.org/10.3324/haematol.2016.151910

Ejemplares similares

Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category
por: Mannelli, Francesco, et al.
Publicado: (2020)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
por: Piccini, Matteo, et al.
Publicado: (2021)

Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion
por: Peruzzi, Benedetta, et al.
Publicado: (2013)

P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Mannelli, Francesco, et al.
Publicado: (2023)

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
por: Pabst, T, et al.
Publicado: (2009)

High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG)
por: Salmoiraghi, Silvia, et al.
Publicado: (2020)

Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’
por: Hou, H-A, et al.
Publicado: (2009)

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia
por: Bassan, R, et al.
Publicado: (2014)

MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL
por: Tosi, Manuela, et al.
Publicado: (2021)

Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes
por: Cavagna, Roberta, et al.
Publicado: (2020)

Bone marrow involvement in small cell lung cancer
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06
por: Caprioli, Chiara, et al.
Publicado: (2020)

Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology
por: Spinelli, Orietta, et al.
Publicado: (2014)

Germline CEBPA mutation in familial acute myeloid leukemia
por: Boada, Matilde, et al.
Publicado: (2021)

Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations
por: Yuan, Ji, et al.
Publicado: (2023)

In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis
por: Guo, Hong, et al.
Publicado: (2016)

Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancer
por: Qiao, Xue, et al.
Publicado: (2021)

Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07
por: Bassan, Renato, et al.
Publicado: (2020)

Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression
por: Liu, Wei, et al.
Publicado: (2019)

Expression level of CEBPA gene in acute lymphoblastic leukemia individuals
por: Szmajda, Dagmara, et al.
Publicado: (2019)

ID1 and CEBPA coordinate epidermal progenitor cell differentiation
por: Kantzer, Christina Geraldine, et al.
Publicado: (2022)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

The Frequency of Granulocytes with Spontaneous Somatic Mutations: A Wide Distribution in a Normal Human Population
por: Rondelli, Tommaso, et al.
Publicado: (2013)

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia
por: Grossmann, V, et al.
Publicado: (2012)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma
por: Setten, Ryan L., et al.
Publicado: (2018)

HoxA9 binds and represses the Cebpa +8 kb enhancer
por: Peng, Lei, et al.
Publicado: (2019)

Prognostic Nomogram for Acute Myeloid Leukemia Patients With Biallelic CEBPA Mutations
por: Xu, Xiaoyu, et al.
Publicado: (2021)

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions
por: Su, Long, et al.
Publicado: (2022)

Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity
por: Chen, Xiufei, et al.
Publicado: (2022)

Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations
por: Salmoiraghi, Silvia, et al.
Publicado: (2020)

Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis
por: Quintana-Bustamante, Oscar, et al.
Publicado: (2012)

Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia
por: Schardt, Julian A, et al.
Publicado: (2010)

CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia
por: Hughes, James M, et al.
Publicado: (2014)

Genetic characterisation of PPARG, CEBPA and RXRA, and their influence on meat quality traits in cattle
por: Goszczynski, Daniel Estanislao, et al.
Publicado: (2016)

Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations
por: Volpe, Giacomo, et al.
Publicado: (2019)

CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex
por: Schmidt, Luisa, et al.
Publicado: (2019)

The regulatory control of Cebpa enhancers and silencers in the myeloid and red-blood cell lineages
por: Repele, Andrea, et al.
Publicado: (2019)

Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia
por: Schmidt, Luisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ufpsj9hk66ifqdh1mfedt8br46